Korsana Biosciences, Inc. (KRSA) Stock Price & Analysis
Korsana Biosciences, Inc. (KRSA) closed at USD 33.65 on Thursday, October 15, 2026, down 1.95% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 34.32; the Oct 15, 2026 session ranged USD 33.43–35.15 on volume of 176,034 shares. Market capitalization is $1.53B, with a 52-week range of USD 7.19–59.36 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/KRSA.md
Key facts (KRSA)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 44 (range 8–70).
- Total return with dividends: 1Y +113.7% vs S&P 500 +18.1%; 5Y -91.1% vs S&P 500 +85.1%.
Analysts (KRSA)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 44 (low 8, high 70).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | Wedbush | Initiated | Outperform | $44 |
| 2026-09-28 | Guggenheim | Initiated | Buy | $70 |
| 2026-09-14 | Stifel | Initiated | Buy | $43 |
| 2026-09-14 | TD Cowen | Initiated | Buy | |
| 2026-09-11 | UBS | Initiated | Buy | $55 |
Total return (dividends reinvested) (KRSA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +113.7% | -91.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +114.2% | -38.2% |
| Volatility (annualized) | 174.8% | 123.3% |
| Max drawdown | -54.7% (Apr 2026→Apr 2026) | -98.1% (Nov 2021→Feb 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 33.65 |
|---|---|
| Change | ▼ 1.95% (down) |
| Previous Close | USD 34.32 |
| Open | USD 34.7 |
| Day Range | USD 33.43 – 35.15 |
| 52-Week Range | USD 7.19 – 59.36 |
| Volume | 176,034 shares |
| Market Cap | $1.53B |
| Exchange | NCM |
Technical Analysis (KRSA)
Nexqual's technical model rates KRSA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.72 (neutral) |
| vs SMA50 | Above (USD 30.11) |
| MACD | 0.89 (positive) |
Analyst Ratings (KRSA)
Wall Street analysts rate KRSA "Buy" based on 5 analysts, with a mean price target of USD 44 (range USD 8–70), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 44 |
| High Target | USD 70 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (KRSA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.19 vs est -0.38 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (KRSA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.01 |
| Current Ratio | 17.4 |
| Total Cash | $134.16M |
| Total Debt | $1.10M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (KRSA)
Nexqual rates Korsana Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $134M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$42M (TTM) |
| Efficiency | Mixed — No data |
Ownership (KRSA)
| Insider Ownership | +0.34% |
|---|---|
| Institutional Ownership | +30.13% |
| Shares Outstanding | 45.54M |
| Float | 4.31M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (KRSA)
Korsana Biosciences, Inc. is led by Jonathan Violin (age 50), President, CEO, Secretary & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| President, CEO, Secretary & Director | Jonathan Violin (age 50) |
|---|---|
| Chief Financial Officer | Mark Joseph Vignola (age 47) |
| Senior Vice President of Finance & Treasurer | Kyle Breidenstine |
Major Backers & Investors (KRSA)
Notable institutional backers of Korsana Biosciences, Inc. include Fidelity, Kalehua Capital Management LLC, FMR, LLC, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 8.81% |
| Kalehua Capital Management LLC | 5.04% |
| FMR, LLC | 1.98% |
| Balyasny Asset Management LP | 0.97% |
| Adar1 Capital Management, LLC | 0.91% |
| Braidwell LP | 0.48% |
| Citadel | 0.18% |
| Variable Insurance Products Fund IV-VIP Health Care Portfolio | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.18% |
| Geode Capital | 0.14% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt